CompletedPhase 3ketamine
Ketamine As an Adjunctive Therapy for Major Depression (2)
Sponsored by University of Dublin, Trinity College
NCT ID
NCT04939649
Target Enrollment
63 participants
Start Date
2021-09-13
Est. Completion
2024-08-12
About This Study
Pragmatic, randomised, controlled, parallel-group, superiority trial of ketamine vs. midazolam as an adjunctive therapy for depression. The main purpose of the trial is to assess the mood-rating score difference between ketamine and midazolam from before the first infusion to 24 hours after the final infusion, supplemented by a 95% confidence interval. There will also be a 24-week follow-up after the final infusion session.
Conditions Studied
Interventions
- •Ketamine
- •Midazolam
Eligibility
Age:18 Years - N/A
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: * ≥18 years old. * Montgomery-Åsberg Depression Rating Scale (MADRS) score ≥ 20 at screening and start of the first infusion. * Voluntary admission for treatment of an acute depressive episode * Meet DSM-5 criteria for a major depressive disorder or bipolar affective disorder (current episode depression). Diagnosis of a major depressive disorder or bipolar affective disorder (DSM-5) will be confirmed by the structured diagnostic Mini International Neuropsychiatric Interview (MINI; updated Version 7 for DSM-5). Exclusion Criteria: * Current involuntary admission. * Medical condition rendering unfit for ketamine/midazolam. * Currently taking any of the contraindicated medications that may alter the pharmacokinetics of ketamine. * Active suicidal intention. * Dementia. * Lifetime history of schizophrenia or schizoaffective disorder; active anorexia nervosa or bulimia nervosa in the past 12 months; alcohol or other substance use disorder (with the exception of nicotine) in the previous six months; any DSM-5 disorder other than a major depressive episode (unipolar or bipolar) as the primary presenting problem. * Electroconvulsive Therapy (ECT) administered within the last two months. * Pregnancy, breastfeeding or considering becoming pregnancy whilst on the trial for up to 12 weeks after last dose or inability to confirm use of adequate contraception during the trial. * Breastfeeding women.
Study Locations (1)
St Patrick's Univeristy Hospital
Dublin, Ireland